Climb Bio (CLYM) Exchange Rate Effect (2020 - 2025)
Climb Bio's (CLYM) quarterly Exchange Rate Effect came in at $24000.0 in Q2 2025, up 26.32% YoY from $19000.0 in Q2 2024, and up 200.0% on a QoQ basis from -$24000.0 in Q1 2025.
Powered by 
Analysis
Climb Bio (CLYM) Exchange Rate Effect (2020 - 2025) Analysis & Trends
Climb Bio (CLYM) has 6 years of Exchange Rate Effect data on file, last reported at $24000.0 in Q2 2025.
- Quarterly Exchange Rate Effect rose 26.32% year-over-year to $24000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $24000.0 (down 47.83% YoY) and the FY2024 annual result came in at $42000.0, down 86.18% from the prior year.
- Exchange Rate Effect grew to $24000.0 in Q2 2025, from -$24000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $1.8 million in Q4 2022 to a low of -$1.1 million in Q2 2022.
- A 5-year average of $10764.7 and a median of $19000.0 in 2024 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2022 — Exchange Rate Effect slumped 1355.7% — and 2024, when it surged 2600.0%.
- Tracing CLYM's Exchange Rate Effect over 5 years: stood at $79000.0 in 2021, then surged by 2193.67% to $1.8 million in 2022, then sank by 118.21% to -$330000.0 in 2023, then jumped by 82.73% to -$57000.0 in 2024, then soared by 142.11% to $24000.0 in 2025.
- The last three Exchange Rate Effect figures came in at $24000.0 (Q2 2025), -$24000.0 (Q1 2025), and -$57000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Climb Bio | 1.18 Bn | 1.18 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Dec 31, 2024 | -57,000.00 |
| Sep 30, 2024 | 108,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | -330,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 399,000.00 |
| Mar 31, 2023 | 231,000.00 |
| Dec 31, 2022 | 1.81 Mn |
| Sep 30, 2022 | -992,000.00 |
| Jun 30, 2022 | -1.05 Mn |
| Mar 31, 2022 | -177,000.00 |
| Sep 30, 2021 | 79,000.00 |
| Jun 30, 2021 | 85,000.00 |
| Mar 31, 2021 | 81,000.00 |
| Dec 31, 2020 | 418,000.00 |
| Sep 30, 2020 | -169,000.00 |